Challenges of denosumab in giant cell tumor of bone, and other giant cell-rich tumors of bone

A Lipplaa, S Dijkstra, H Gelderblom - Current opinion in oncology, 2019‏ - journals.lww.com
For the related but heterogenous group of giant cell rich tumors of bone, like aneurysmal
bone cysts (ABC) and central giant cell granuloma (CGCG), denosumab is a new treatment …

Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature

G Luengo-Alonso, M Mellado-Romero… - Archives of orthopaedic …, 2019‏ - Springer
Background Denosumab is a human monoclonal antibody (mAb) that specifically inhibits
tumor-associated bone lysis through the RANKL pathway and has been used as …

[HTML][HTML] Denosumab in giant cell tumor of bone: multidisciplinary medical management based on pathophysiological mechanisms and real-world evidence

AM Borkowska, A Szumera-Ciećkiewicz… - Cancers, 2022‏ - mdpi.com
Simple Summary The widely accepted local therapy in extremity giant cell tumor of bone
(GCTB) is surgery, in the form of extended intralesional curettage with adequate disease …

[HTML][HTML] Managements of giant cell tumor within the distal radius: a retrospective study of 58 cases from a single center

C Zou, T Lin, B Wang, Z Zhao, B Li, X **e… - Journal of bone …, 2019‏ - Elsevier
Background Giant cell tumor of bone (GCTB) in distal radius is a benign but invasive bone
tumor characterized by strong aggressive behavior and frequent recurrence. Methods To …

[PDF][PDF] Evaluation of local recurrence in giant-cell tumor of bone treated by neoadjuvant denosumab

PS Chinder, S Hindiskere… - Clinics in orthopedic …, 2019‏ - synapse.koreamed.org
Background Giant-cell tumor of bone (GCTB) is a locally aggressive primary benign tumor
presenting as an expansile osteolytic lesion affecting the epiphysis of long bones …

Treatment of recurrent giant cell tumor of bones: a systematic review

C Pitsilos, P Givissis, P Papadopoulos, B Chalidis - Cancers, 2023‏ - mdpi.com
Simple Summary There is limited evidence in the current literature about the best
management of the recurrent giant cell tumor of bones (GCTB). The aim of this systematic …

Role of (Neo) adjuvant denosumab for giant cell tumor of bone

E Palmerini, EL Staals, LB Jones, DM Donati… - … treatment options in …, 2020‏ - Springer
Opinion statement Denosumab is a RANK ligand inhibitor approved for the treatment of
giant cell tumor of bone. While the role of denosumab in the setting of advanced and …

Short‐term Preoperative Denosumab With Surgery in Unresectable or Recurrent Giant Cell Tumor of Bone

R Zhang, T Ma, D Qi, M Zhao, T Hu… - Orthopaedic …, 2019‏ - Wiley Online Library
Objective The purpose of this retrospective study was to evaluate the clinical and
oncological results of combination treatment of short‐term preoperative denosumab (the …

Giant cell tumor of bone: Unusual features of a rare tumor

ZM Mohaidat, HZ Al-Jamal, AM Bany-Khalaf… - Rare …, 2019‏ - journals.sagepub.com
Giant cell tumor of bone is a benign tumor with an aggressive behavior. Its typical
subarticular location and high recurrence risk can be associated with significant morbidity …

Denosumab for effective tumor size reduction in patients with giant cell tumors of the bone: a systematic review and meta-analysis

J Yayan - Cancer Control, 2020‏ - journals.sagepub.com
Background: Denosumab is a human monoclonal antibody that has been used successfully
in the treatment of giant cell tumors of bone. These tumors are rare and, in principle, benign …